Yahoo · Sep 23, 2026
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
European equities traded in the US as American depositary receipts were tracking lower Wednesday mor
EV
NASDAQ · EVAX
Evaxion Biotech A/S
Healthcare · Biotechnology
$3.05
Down-$0.11 (-3.48%)
Updated Oct 9, 2026, 4:02 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 40.36M
- P/E ratio
- -11.8
- Dividend yield
- 0.00%
- 52-week range
- $2.77 – $4.75
- Volume
- 63.97K
- Avg. volume
- 1.63M
Price performance · EVAX
EVAX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 8, 2026
EVAX closed at $3.05 after 21 trading sessions, down 1.61% for the selected period.
- Last close
- $3.05
- Period change
- -1.61%
- Period low
- $3.03
- Period high
- $3.34
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 8, 2026 | $3.18 | $3.23 | $3.02 | $3.05 | 63.97K |
| Oct 7, 2026 | $3.16 | $3.25 | $3.11 | $3.16 | 21.75K |
| Oct 6, 2026 | $3.24 | $3.25 | $3.12 | $3.16 | 35.87K |
| Oct 5, 2026 | $3.20 | $3.24 | $3.14 | $3.15 | 38.24K |
| Oct 2, 2026 | $3.23 | $3.2751 | $3.1558 | $3.20 | 33.92K |
| Oct 1, 2026 | $3.25 | $3.29 | $3.13 | $3.18 | 38.12K |
| Sep 30, 2026 | $3.35 | $3.35 | $3.2422 | $3.28 | 18.05K |
| Sep 29, 2026 | $3.20 | $3.31 | $3.20 | $3.27 | 38.14K |
| Sep 28, 2026 | $3.34 | $3.35 | $3.19 | $3.24 | 55.69K |
| Sep 25, 2026 | $3.30 | $3.35 | $3.24 | $3.34 | 45.06K |
| Sep 24, 2026 | $3.30 | $3.35 | $3.25 | $3.26 | 36.87K |
| Sep 23, 2026 | $3.33 | $3.35 | $3.2415 | $3.2801 | 35.21K |
| Sep 22, 2026 | $3.18 | $3.31 | $3.18 | $3.27 | 32.4K |
| Sep 21, 2026 | $3.24 | $3.25 | $3.17 | $3.21 | 36.89K |
| Sep 18, 2026 | $3.22 | $3.33 | $3.16 | $3.27 | 43.34K |
| Sep 17, 2026 | $3.10 | $3.25 | $3.05 | $3.22 | 53.34K |
| Sep 16, 2026 | $3.03 | $3.24 | $3.00 | $3.03 | 73.87K |
| Sep 15, 2026 | $3.12 | $3.15 | $3.0001 | $3.04 | 11.17K |
| Sep 14, 2026 | $3.17 | $3.17 | $3.07 | $3.07 | 21.87K |
| Sep 11, 2026 | $3.17 | $3.1995 | $3.10 | $3.13 | 30.26K |
| Sep 10, 2026 | $3.29 | $3.29 | $3.05 | $3.10 | 87.19K |
Latest EVAX news
The latest Smart Investors Daily articles mentioning EVAX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
EVAX research
Overview
Company profile and research snapshot.
Company profile
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $13.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 24, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 10, 2026 | Jones Trading | Buy | — |
| Mar 9, 2026 | Lake Street | Buy | — |
| Mar 9, 2026 | HC Wainwright & Co. | Buy | — |
| Oct 30, 2025 | Edward Jones | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 22, 2026
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
European equities traded in the US as American depositary receipts Tuesday were tracking lower Tuesd
Yahoo · Sep 18, 2026
European Equities Traded in the US as American Depositary Receipts Drop in Friday Trading
European equities traded in the US as American depositary receipts were heading lower late Friday mo
Yahoo · Sep 14, 2026
Evaxion applies its AI-Immunology™ platform in autoimmune diseases
Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology™ to target underlying pathologiesThe unique capabilities of AI-Immunology™ could potentially help develop new treatments with higher efficacy and less side effects than current treatmentsInitial experimental data will be presented at the Protein & Antibody Engineering Summit (PEGS) Europe taking place in Lisbon, Portugal, on November 18, 2026 CO
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
